[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Gómez Portilla A, Cendoya I, Muriel J, Olabarria I, Guede N, Moraza N, Fernández E, Martínez de Lecea C, Magrach L, Martín E, Romero E, Aguado I, Valdovinos M, Larrabide I: [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]. Cir Esp; 2007 Feb;81(2):82-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
  • [Transliterated title] Mesotelioma peritoneal maligno. Nuestra experiencia con la triple terapia combinada: citorreducción, quimioterapia intraperitoneal perioperatoria e hipertermia.
  • INTRODUCTION: Malignant peritoneal mesothelioma is the most common primary neoplasm of the serous peritoneum.
  • Prognosis with traditional therapeutic options is dismal, with a median survival of between 4 and 12 months from diagnosis.
  • The application of a new combined therapy with cytoreductive surgery, intraperitoneal perioperative chemotherapy and heated intraperitoneal intraoperative chemotherapy, followed by early postoperative intraperitoneal chemotherapy is currently providing good results, in some instances even allowing curative intent.
  • We present a series of patients treated with this triple combined therapy.
  • Among these patients, surgery was performed on 11 occasions in seven patients with a diffuse malignant peritoneal mesothelioma.
  • RESULTS: Eleven cytoreductions were performed in seven patients with diffuse malignant peritoneal mesothelioma.
  • There were four men and three women, with a mean age of 50 years (range 31-57 years).
  • Only two patients had also received systemic chemotherapy as adjuvant treatment after their initial diagnosis, as the only possible therapeutic alternative.
  • Treatment with curative intent was provided, obtaining complete cytoreduction of macroscopic disease in all patients, followed by application of intraperitoneal perioperative chemotherapy for the treatment of any residual microscopic disease.
  • Pathologic analysis showed biphasic sarcomatous mesothelioma in two patients and epithelial mesothelioma in the remaining five patients.
  • Three patients died from disease progression at 3, 9 and 11 months after the initial cytoreduction; of these, two patients had diffuse biphasic sarcomatous mesothelioma.
  • The remaining four patients are still alive at 5, 9, 19 and 54 months after the initial cytoreduction without evidence of disease at the present time.
  • CONCLUSIONS: Radical oncologic cytoreductive surgery combined with intraperitoneal perioperative chemotherapy provides good results with prolonged survival in selected cases, although morbidity is high.
  • Based in our experience, biphasic sarcomatous mesotheliomas should be excluded from this protocol because of their aggressiveness; these tumors should be included only in conventional therapeutic strategies with palliative intent.
  • [MeSH-major] Mesothelioma / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Male. Middle Aged

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306123.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Tanzi S, Tiseo M, Internullo E, Cacciani G, Capra R, Carbognani P, Rusca M, Rindi G, Ardizzoni A: Localized malignant pleural mesothelioma: report of two cases. J Thorac Oncol; 2009 Aug;4(8):1038-40
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant pleural mesothelioma: report of two cases.
  • Localized malignant pleural mesothelioma is very rare tumor disease.
  • There are sporadic reports in the literature showing that this entity has a different biologic behavior compared with diffuse pleural mesothelioma.
  • We report two cases of radically resected localized pleural malignant mesothelioma, with a previous history of asbestos exposure.
  • Both cases showed a microscopic and immunohistochemical findings of malignant mesothelioma, biphasic and sarcomatoid lympho-histiocitoid variant type, respectively, without evidence of diffuse pleural spread.
  • The first is very peculiar case of bilateral localized malignant pleural mesothelioma with complete response to chemotherapy and localized late recurrence, radically resected and treated with adjuvant radiotherapy.
  • Both cases demonstrate that the localized malignant mesothelioma should be distinguished from diffuse form and that complete resection is associated with good prognosis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633479.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Suárez Antelo J, Rodríguez García C, Montero Martínez C, Verea Hernando H: [Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: a case report and a review of the literature]. Arch Bronconeumol; 2010 Jan;46(1):44-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: a case report and a review of the literature].
  • [Transliterated title] Sarcoma de Ewing pulmonar/tumor neuroectodérmico primitivo (PNET): aportación de un caso y revisión de la bibliografía.
  • The most common intrathoracic variants are synovial sarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, and sarcomatoid mesothelioma.
  • Although thoracic Ewing sarcoma/primitive neuroectodermal tumor (PNET) usually develops on the chest wall, there have been reports of primary Ewing sarcoma/PNET of the lung.
  • We present the case of a 22-year-old woman with Ewing sarcoma/PNET diagnosed following histologic, immunohistochemical, and in situ hybridization studies of a bronchial biopsy specimen.
  • The patient was started on a chemotherapy regimen of vincristine, actinomycin, cyclophosphamide, doxorubicin, ifosfamide, and etoposide and responded well.
  • [MeSH-major] Lung Neoplasms. Neuroectodermal Tumors, Primitive. Sarcoma, Ewing

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 SEPAR. Published by Elsevier Espana. All rights reserved.
  • (PMID = 19656607.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


Advertisement
4. Kusama T, Kodaka T, Tsunemine H, Akasaka H, Koizumi N, Fujimoto K, Sakano S, Ito R, Kondo T, Kitazawa S, Yamamura H, Takahashi K: [A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)]. Gan To Kagaku Ryoho; 2009 Mar;36(3):475-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)].
  • A computed tomography(CT)revealed massive tumors in abdominal cavity.
  • By using immunohistochemical staining, the patient was diagnosed as sarcomatoid malignant peritoneal mesothelioma.
  • We started a combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine (CYVADIC).
  • The recurrent tumors showed remarkable reduction after the two courses of CYVADIC chemotherapy.
  • Although we next started carboplatin and paclitaxel combination chemotherapy, she died due to rapidly progression of the disease with disseminated intravascular coagulation after 132 days of the operation.
  • Malignant mesothelioma, especially sarcomatoid mesothelioma, is known to have a poor prognosis.
  • However, our case suggests that we could improve the prognosis of sarcomatoid malignant mesothelioma by aggressive chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Mesothelioma / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease Progression. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295275.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B: Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther; 2008 Mar;7(3):569-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.
  • Mesothelioma is a malignancy of the mesothelium and current treatments are generally ineffective.
  • One promising area of anticancer drug development is to explore tumor susceptibility to targeted therapy.
  • To achieve efficient, targeted intracellular delivery of therapeutic agents to mesothelioma cells, we selected a naive human single-chain (scFv) phage antibody display library directly on the surface of live mesothelioma cells to identify internalizing antibodies that target mesothelioma-associated cell surface antigens.
  • We have identified a panel of internalizing scFvs that bind to mesothelioma cell lines derived from both epithelioid (M28) and sarcomatous (VAMT-1) types of this disease.
  • Most importantly, these antibodies stain mesothelioma cells in situ and therefore define a panel of clinically represented tumor antigens.
  • We have further exploited the internalizing function of these scFvs to achieve targeted intracellular drug delivery to mesothelioma cells.
  • We showed that scFv-targeted immunoliposomes were efficiently and specifically taken up by both epithelioid and sarcomatous mesothelioma cells, but not control cells, and immunoliposomes encapsulating the small-molecule drug topotecan caused targeted killing of both types of mesothelioma cells in vitro.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):2012-20 [17660511.001]
  • [Cites] Anal Biochem. 2000 Nov 1;286(1):119-28 [11038282.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 17;53(2):171-216 [11731026.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1597-608 [12000712.001]
  • [Cites] J Mol Biol. 2002 Aug 2;321(1):49-56 [12139932.001]
  • [Cites] Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118 [12183061.001]
  • [Cites] Toxicol Ind Health. 2001 Jun;17(5-10):247-53 [12539869.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3154-61 [12810643.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Sep;52(3):253-61 [12783198.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):704-10 [14744788.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S103-19 [15261443.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S125-7 [15261445.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Biochim Biophys Acta. 1980 Oct 2;601(3):559-71 [6251878.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2610-5 [1568228.001]
  • [Cites] J Pharm Sci. 1992 Jul;81(7):676-84 [1403703.001]
  • [Cites] Hum Pathol. 1994 Mar;25(3):227-34 [7512071.001]
  • [Cites] J Pathol. 1996 Aug;179(4):358-69 [8869281.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Immunol Methods. 1997 Feb 28;201(2):223-31 [9050944.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4811-6 [9354443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6157-62 [9600934.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):L165-71 [9688948.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Adv Anat Pathol. 1998 Jan;5(1):53-60 [9868512.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 16;255(2):386-93 [10049718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6953-8 [10359820.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12486-93 [15615731.001]
  • [Cites] Biotechnol Prog. 2005 Jan-Feb;21(1):221-32 [15903261.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Med Lav. 2005 Jul-Aug;96(4):287-303 [16457426.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):417-28 [16415794.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):533-40 [16321969.001]
  • [Cites] Int J Occup Environ Health. 2006 Jan-Mar;12(1):9-15 [16523977.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3271-7 [16540680.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):294-301 [16809158.001]
  • [Cites] Mol Cell Proteomics. 2006 Dec;5(12):2350-63 [16971384.001]
  • [Cites] Mol Cell Proteomics. 2006 Dec;5(12):2364-73 [16982673.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):177-9 [17409851.001]
  • [Cites] J Mol Med (Berl). 2007 Oct;85(10):1113-23 [17554518.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] J Mol Biol. 2000 Sep 1;301(5):1149-61 [10966812.001]
  • (PMID = 18319332.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118919-02; United States / NCI NIH HHS / CA / R01 CA118919-03; United States / NCI NIH HHS / CA / CA 95671; United States / NCI NIH HHS / CA / R01 CA095671; United States / NCI NIH HHS / CA / R01 CA118919-01; United States / NCI NIH HHS / CA / CA118919-01; United States / NCI NIH HHS / CA / R01 CA 118919; United States / NCI NIH HHS / CA / R01 CA118919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antineoplastic Agents; 0 / Immunoglobulin Fragments
  • [Other-IDs] NLM/ NIHMS78089; NLM/ PMC2943512
  •  go-up   go-down


6. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • FNAC of these nodules reveled pleomorphic malignant spindle shaped cell with epithelioid morphology.
  • The subcutis is a particularly rare site of metastatic sarcomatoid mesothelioma.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlöf AK, Fernandes AP, Björnstedt M, Dobra K: Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res; 2009;28:92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.
  • BACKGROUND: Selenite is a promising anticancer agent which has been shown to induce apoptosis in malignant mesothelioma cells in a phenotype-dependent manner, where cells of the chemoresistant sarcomatoid phenotype are more sensitive.
  • METHODS: In this paper, we investigate the apoptosis signalling mechanisms in sarcomatoid and epithelioid mesothelioma cells after selenite treatment.
  • Bax was up-regulated only in the sarcomatoid cell line, while the epithelioid cell line down-regulated Bcl-XL and showed greater caspase-3 activation.
  • Chemical inhibition of p53 did not protect the cells from apoptosis. p53 lost its DNA binding ability after selenite treatment and was enriched in an inactive form.
  • Levels of thioredoxin decreased after selenite treatment.
  • CONCLUSION: We delineate pathways of apoptosis signalling in response to selenite, showing differences between epithelioid and sarcomatoid mesothelioma cells.
  • These differences may partly explain why sarcomatoid cells are more sensitive to selenite.
  • [MeSH-major] Apoptosis / drug effects. Mesothelioma / drug therapy. Mesothelioma / pathology. Signal Transduction / drug effects. Sodium Selenite / pharmacology
  • [MeSH-minor] Caspase 3 / metabolism. Cell Proliferation. Flow Cytometry. Humans. Immunoenzyme Techniques. Luciferases / metabolism. Membrane Potential, Mitochondrial / drug effects. Phenotype. Proto-Oncogene Proteins c-bcl-2 / metabolism. Thioredoxins. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37474-80 [10982790.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] Differentiation. 2000 Dec;66(4-5):181-8 [11269944.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30542-51 [11375392.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):1017-24 [12082024.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):253-9 [12201488.001]
  • [Cites] Carcinogenesis. 2002 Oct;23(10):1609-15 [12376468.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1059-66 [12481429.001]
  • [Cites] Antioxid Redox Signal. 2003 Jun;5(3):273-9 [12880482.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12):2301-11 [14637188.001]
  • [Cites] Biochem Pharmacol. 2004 Feb 1;67(3):513-22 [15037203.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):354-62 [15172356.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):877-84 [15252149.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S103-19 [15261443.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4407-12 [8813134.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3633-8 [9108029.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] Mol Carcinog. 1998 Mar;21(3):205-14 [9537652.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):280-9 [9925742.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):820-8 [10328239.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3175-9 [10397262.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Histochem Cytochem. 2005 Feb;53(2):141-53 [15684327.001]
  • [Cites] Biochem Cell Biol. 2005 Apr;83(2):196-211 [15864328.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1827-40 [15920167.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3853-63 [15824742.001]
  • [Cites] J Pathol. 2005 Sep;207(1):91-101 [16007577.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1618-22 [16118627.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):218-25 [16173037.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2296-304 [16489034.001]
  • [Cites] Apoptosis. 2006 Feb;11(2):143-9 [16502253.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1873-82 [16891474.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):2078-85 [16928829.001]
  • [Cites] Free Radic Biol Med. 2006 Sep 15;41(6):874-85 [16934670.001]
  • [Cites] Differentiation. 2007 Feb;75(2):123-32 [17316382.001]
  • [Cites] J Pathol. 2007 Mar;211(4):447-54 [17253596.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):145-50 [17346688.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):591-601 [17409924.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):986-94 [17350081.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6314-24 [17616690.001]
  • [Cites] Cell Biol Toxicol. 2008 Apr;24(2):123-41 [17610029.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] Connect Tissue Res. 2008;49(3):270-2 [18661358.001]
  • [Cites] BMB Rep. 2008 Oct 31;41(10):745-50 [18959823.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jan;63(2):351-62 [18379781.001]
  • [Cites] Cell Physiol Biochem. 2008;22(5-6):387-94 [19088420.001]
  • [Cites] Biol Trace Elem Res. 2009 Mar;127(3):200-10 [18953506.001]
  • [Cites] Biochem Pharmacol. 1993 Jan 26;45(2):429-37 [8382065.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4469-73 [8402615.001]
  • [Cites] Biochem Pharmacol. 1995 Jul 17;50(2):213-9 [7632165.001]
  • [Cites] Nutr Cancer. 2009;61(2):251-64 [19235042.001]
  • [Cites] Nutr Cancer. 2009;61(3):397-407 [19373614.001]
  • [Cites] Free Radic Biol Med. 2009 Apr 15;46(8):1186-96 [19439215.001]
  • [Cites] Ann Hematol. 2009 Aug;88(8):733-42 [19153735.001]
  • [Cites] Cancer Lett. 2009 Sep 8;282(1):116-23 [19345479.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6118-22 [2790824.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35809-15 [10585464.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3508-15 [10589765.001]
  • [Cites] Free Radic Biol Med. 2001 Jan 1;30(1):9-21 [11134891.001]
  • (PMID = 19563663.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 52500-60-4 / Thioredoxins; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3; HIW548RQ3W / Sodium Selenite
  • [Other-IDs] NLM/ PMC2711967
  •  go-up   go-down


8. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Kuroda K, Ishizawa S, Kudo T, Uotani H, Hosokawa A, Tanaka T, Kitano H, Hori T, Tsukada K, Sugiyama T, Fukuoka J: Localized malignant mesenteric mesothelioma causing small bowel obstruction. Pathol Int; 2008 Apr;58(4):239-43
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant mesenteric mesothelioma causing small bowel obstruction.
  • Malignant mesothelioma is an uncommon lethal neoplasm in the serous membrane in which peritoneal mesothelioma is a rarer form.
  • Herein is reported a case of malignant mesothelioma presenting as a localized mass inside the mesentery causing focal luminal obstruction of the small intestine.
  • The diagnosis of malignant mesothelioma was obtained on repeat double balloon endoscopic biopsy.
  • Partial resection of the small intestine along with the mesentery was performed, followed by a course of chemotherapy.
  • To the best of the authors' knowledge this is the first reported case of localized malignant mesothelioma arising inside the mesentery.
  • Mesothelioma should be considered as the differential diagnosis when small bowel obstruction occurs with unknown primary neoplasm.
  • [MeSH-major] Intestinal Obstruction / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Endoscopy, Gastrointestinal. Epithelioid Cells / pathology. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324917.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Togashi K, Hosaka Y, Sato K: [Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia]. Kyobu Geka; 2007 Jan;60(1):49-52
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia].
  • Radiological studies demonstrated a solid mass with a maximal diameter of 5cm at the posterior mediastinum.
  • The tumor was resected, then postoperative radiotherapy (60Gy) and chemotherapy were performed.
  • Results of histological and immunohistochemical study showed that the tumor consisted of sarcomatoid mesothelioma.
  • Case 2: A 76-year-old man with dysphagia, chest pain and cough admitted to our department Radiological studies demonstrated a solid mass with a maximal diameter of 12cm in the posterior mediastinum. accompanied by abundant effusion in the bilateral pleural cavities.
  • The patient underwent open biopsy and histological and immunohistochemical study showed that the tumor consisted of sarcomatoid mesothelioma.
  • We report extremely rare cases of sarcomatoid mesothelioma that appeared to be posterior mediastinal tumor before surgery, and discuss the difficulty of diagnosing sarcomatoid mesothelioma with atypical clinical manifestations.
  • [MeSH-major] Deglutition Disorders / complications. Mediastinal Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249539.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Winfree CJ, Mack WJ, Sisti MB: Solitary cerebellar metastasis of malignant pleural mesothelioma: case report. Surg Neurol; 2004 Feb;61(2):174-8; discussion 178-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary cerebellar metastasis of malignant pleural mesothelioma: case report.
  • BACKGROUND: Malignant pleural mesothelioma is an uncommon malignancy that rarely metastasizes to the central nervous system and even less frequently occurs as a solitary lesion.
  • She presented with a 15-lb. weight loss over several months and persistent right subscapular pain radiating to her anterior chest.
  • Imaging studies revealed a pleural mass, and biopsy confirmed fibrous type malignant pleural mesothelioma.
  • During a metastatic workup, computed tomography (CT) and magnetic resonance imaging (MRI) of the head demonstrated a 1 cm subcortical, contrast-enhancing lesion without surrounding edema in the right posterior cerebellum.
  • Surgical resection of the solitary cerebellar mass revealed fibrous-type metastatic malignant mesothelioma.
  • Postoperatively, the patient received a combined chemotherapy regimen of Adriamycin and Cisplatin and underwent whole brain radiation therapy.
  • CONCLUSIONS: We report the first resection of a solitary cerebellar metastasis of malignant pleural mesothelioma.
  • We also review past cases of intracranial metastasis of this malignancy, its histologic subtypes, outcome, and recent treatment modalities.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Mesothelioma / secondary. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751636.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


12. Gulmez I, Kart L, Buyukoglan H, Er O, Balkanli S, Ozesmi M: Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J; 2004 May-Jun;11(4):287-90
Hazardous Substances Data Bank. Erionite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.
  • BACKGROUND: Malignant mesothelioma (MM) is a fatal neoplasm which frequently results from exposure to asbestos or erionite.
  • Their clinical and radiological features, as well as the therapy, were retrospectively evaluated.
  • Pleural effusion (92.4%) was the most common chest x-ray finding, whereas pleural effusion (60.8%), pleural nodules (34.7%) and pleural thickening (34.7%) were the most common computed tomography findings in pleural MM patients.
  • The histological subtypes of MM were determined as epithelial in 60 patients (89.5%), sarcomatous in four patients (5.9%) and mixed in three patients (4.4%).
  • Thirty-five patients (52.2%) were administered chemotherapy, and follow-up data were available for 22 patients.
  • MM is a major public health problem in parts of Turkey and compulsory environmental control of fibrous mineral should be considered.
  • [MeSH-major] Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Environmental Exposure. Female. Humans. Male. Middle Aged. Pleural Effusion / etiology. Tomography, X-Ray Computed. Turkey / epidemiology. Zeolites / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can Respir J. 2004 May-Jun;11(4):273-4 [15254607.001]
  • (PMID = 15254610.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 12510-42-8 / erionite; 1318-02-1 / Zeolites; 1332-21-4 / Asbestos
  •  go-up   go-down


13. Tamura E, Kozaki M, Kunimoto M, Tokuyama S, Kawanami Y, Watanabe H, Hamada T, Morooka M, Mukae H: [A case of localized malignant pleural mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):511-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of localized malignant pleural mesothelioma].
  • A chest computed tomography (CT) scan revealed a 5-cm mass attached to the pleura involving the right upper lobe, and a nodule in the right middle lobe.
  • Transbronchial lung biopsy was performed twice, but no definitive diagnosis was achieved.
  • 18-fluorodeoxyglucose positron emission tomography showed abnormal uptake in the chest lesion.
  • Chemotherapy was initiated for advanced-stage lung cancer, but was not effective.
  • Histopathologic and immunohistochemical examinations after CT-guided needle biopsy revealed malignant mesothelioma.
  • This is a rare and important case of localized malignant mesothelioma pathologically confirmed by biopsy.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684215.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Pistolesi M, Rusthoven J: Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest; 2004 Oct;126(4):1318-29
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
  • The diagnosis and management of malignant pleural mesothelioma are major challenges that often frustrate both patient and clinician alike.
  • Other mineral fibers such as erionite, a naturally occurring fibrous zeolite crystal, are associated with mesothelioma in volcanic tuffs of the Cappadocia region of central Anatolia in Turkey.
  • In addition, other possible factors such as the presence of simian virus 40 and genetic susceptibility have been associated recently with the development of mesothelioma in animal models.
  • In addition, the discovery of elevated levels of various markers such as folic acid receptor alpha, cyclooxygenase 2, and multidrug resistance proteins 1 and 2 in mesothelioma tissue have opened up new areas of potential diagnostic and therapeutic importance.
  • However, traditional treatment modalities--surgery, radiotherapy, and chemotherapy--have evolved slowly, and few gains in therapeutic efficacy have occurred.
  • Recently, however, continuing research efforts have led to novel treatment strategies that are changing the way clinicians view a disease that has traditionally been managed with almost universal therapeutic nihilism.
  • This review explores our current knowledge of this disease and presents current and novel therapeutic strategies.
  • [MeSH-major] Guanine / analogs & derivatives. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glutamates / pharmacology. Glutamates / therapeutic use. Humans. Immunohistochemistry. Neoplasm Staging. Palliative Care. Pemetrexed. Pleurodesis. Prognosis. Thoracoscopy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2005 Aug;128(2):1068; author reply 1068 [16100214.001]
  • (PMID = 15486399.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 104
  •  go-up   go-down


15. Emri S, Akbulut H, Zorlu F, Dinçol D, Akay H, Güngen Y, Içli F: Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer; 2001 Aug-Sep;33(2-3):109-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) due to environmental exposure to asbestos and erionite is a relatively common cancer in Turkey.
  • In this study, we investigated the value of flow cytometric (FCM) DNA analysis and other prognostic factors such as age and etiologic factor in the patients with MPM, treated with surgery+/-combination chemotherapy+/-radiotherapy.
  • A total of 40 patients with a median age of 50 (range 30-68) were included in the study.
  • Twenty-nine patients had asbestos exposure in etiology, while 11 had fibrous zeolite (erionite).
  • [MeSH-major] DNA, Neoplasm / analysis. Mesothelioma / genetics. Pleural Neoplasms / genetics


16. Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou Fernandes A, Björnstedt M, Dobra K: Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med; 2006 Sep 15;41(6):874-85
Hazardous Substances Data Bank. SODIUM SELENITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress.
  • Malignant mesothelioma cells differentiate into sarcomatoid or epithelioid phenotypes.
  • The sarcomatoid cell type is more resistant to chemotherapy and gives a worse prognosis.
  • We have investigated whether selenite alone and in combination with doxorubicin induced apoptosis in variously differentiated mesothelioma cells.
  • Selenite in concentrations that could potentially be administered to patients strongly inhibited the growth of the sarcomatoid mesothelioma cells (IC50 = 7.5 microM), whereas epithelioid cells were more sensitive to doxorubicin.
  • Benign mesothelial cells remained largely unaffected.
  • Selenite potentiated doxorubicin treatment.
  • This offers a possible mechanism of action of selenite treatment.
  • Our findings suggest that selenite is a promising new drug for the treatment of malignant mesothelioma.
  • [MeSH-major] Apoptosis / drug effects. Mesothelioma / pathology. Oxidative Stress / physiology. Sodium Selenite / toxicity
  • [MeSH-minor] Adenocarcinoma. Cell Line, Tumor. Cell Survival / drug effects. Glutathione Peroxidase / metabolism. Humans. Sulfhydryl Compounds / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Free Radic Biol Med. 2006 Sep 15;41(6):862-5 [16934666.001]
  • (PMID = 16934670.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sulfhydryl Compounds; EC 1.11.1.9 / Glutathione Peroxidase; HIW548RQ3W / Sodium Selenite
  •  go-up   go-down


17. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • It is characterized by atypical solid growth of mesothelium with formation of atypical cavities surrounded by fibrous stroma.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


18. Kawamata O, Kondu Y, Murata T, Uetsuka H, Uda M, Nakai H, Ohta T: [Malignant pleural mesothelioma]. Kyobu Geka; 2007 Jan;60(1):31-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma].
  • Malignant pleural mesothelioma carries a poor prognosis, for which no standard therapy has been established.
  • We report 15 cases of malignant pleural mesothelioma experienced since 2000 focusing on their clinical features.
  • Histology of the pleural biopsy specimen showed epithelial mesothelioma in 8 patients, biphasic mesothelioma in 3, sarcomatous mesothelioma in 2 and desmoplastic malignant mesothelioma (DMM) in 2.
  • Twelve patients received chemotherapy.
  • In addition to 2 of these 3 patients, 2 underwent extrapleural pneumonectomy (EPP) without adjuvant treatment.
  • Remaining 1 received palliative treatment only.
  • The longest survival time with chemotherapy is 41 months in a surviving patient with epithelial mesothelioma and that with EPP is 25 months in a surviving patient with DMM.
  • The 2-year survival rate of the 14 patients was 44.4% and the median survival time in patients with epithelial mesothelioma was 30.6 months.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249535.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F, Baas P: Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest; 2001 Oct;120(4):1167-74
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
  • OBJECTIVE: To determine the optimal administered dose of meta-tetrahydroxyphenylchlorin (mTHPC) for intraoperative photodynamic therapy (IPDT) in resected malignant pleural mesothelioma (MPM).
  • The primary objective of this combination treatment was to improve local tumor control.
  • Epithelial mesotheliomas were found in 17 patients, a sarcomatous mesothelioma was found in 1 patient, and mixed epithelial sarcomatous mesotheliomas were found in 10 patients.
  • The real-time fluence rate measurements were performed using four isotropic detectors in the chest cavity to calculate the total light dose.
  • Three patients died in the perioperative period, and one death was directly related to photodynamic therapy.
  • Real-time dosimetry identified 12 patients in whom additional illumination had to be given to the diaphragmatic sinuses, which were unavoidably shielded during integral illumination.
  • The median survival time for all 28 patients was 10 months.
  • Local tumor control, 9 months after treatment, was achieved in 13 of the 26 patients treated with IPDT.
  • CONCLUSION: IPDT using mTHPC, combined with a pleuropneumonectomy, resulted in local control of disease in 50% of the treated cases.
  • The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use.
  • [MeSH-major] Intraoperative Care. Mesothelioma / surgery. Photochemotherapy. Pleural Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Mesoporphyrins / administration & dosage. Mesoporphyrins / adverse effects. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2002 Nov;122(5):1866-7; author reply 1867 [12426299.001]
  • (PMID = 11591556.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; FU21S769PF / temoporfin
  •  go-up   go-down


20. Vander Salm TJ: Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg; 2000 Apr;12(2):89-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The last 3 may also be malignant.
  • The malignant tumors consist of various sarcomas: myxosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, leiomyosarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma, reticulum cell sarcoma, neurofibrosarcoma, and malignant fibrous histiocytoma.
  • The echocardiographic appearance may also allow quite accurate prediction of the tumor type and whether it is malignant or benign.
  • Magnetic resonance imaging serves as the next most important test where the density of T1 and T2 images may allow tumor cell type identification.
  • Many of the malignant tumors cannot be resected completely, either because of the extent of local spread and invasion or because of the frequent distant metastases.
  • For patients with unresectable sarcomas, radiation and chemotherapy may be used, but without great expectation of successful results.
  • [MeSH-minor] Fibroma / diagnosis. Fibroma / surgery. Hamartoma / diagnosis. Hamartoma / surgery. Heart Septum / pathology. Heart Transplantation. Hemangioma / diagnosis. Hemangioma / surgery. Humans. Hypertrophy. Mesothelioma / diagnosis. Mesothelioma / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Prognosis. Rhabdomyoma / diagnosis. Rhabdomyoma / surgery. Teratoma / diagnosis. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807431.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 69
  •  go-up   go-down


21. Pala C, Paliogiannis P, Serventi F, Trignano E, Trignano M: Multimodality approach to malignant pleural mesothelioma. A case report. Ann Ital Chir; 2010 Jan-Feb;81(1):37-40
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality approach to malignant pleural mesothelioma. A case report.
  • INTRODUCTION: We report a case of diffuse malignant pleural mesothelioma (DMPM) in a 68-years-old male patient who was admitted for right sited pleural effusion.
  • The patient was treated by multimodality approach consisting in surgical treatment with Extrapleural Pleuropneumonectomy followed by chemotherapy with Cisplatin and Pemetrexed.
  • Histological examination of the specimens extracted revealed the presence of epithelial malignant pleural mesothelioma with sarcomatoid areas.
  • Extrapleural pleuropneumonectomy was performed followed by a chemiotherapic treatment with Cisplatin and Pemetrexed.
  • DISCUSSION: Single treatments do not demonstrate an acceptable efficacy on the treatment of DMPM.
  • Multimodality therapy provides good survival improvement and acceptable quality of life for the patients.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593749.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Macák J, Mukensnábl P, Kawano N, Bobot L, Dusková M, Vácha P: [Intra-abdominal desmoplastic small-cell tumor of the peritoneum]. Cesk Patol; 2003 Apr;39(2):69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one case, a 22-year-old woman presented with a symptomless course of disease documented by medical examination one month ago.
  • Intensive chemotherapy was applied but two patients died of generalisation.
  • The "classical" type of IDSRT was found in all the cases.
  • Sharply demarcated groups of tumour cells of different size were surrounded by dense fibrous stroma.
  • Many different tumour types, such as lymphoma, Ewing sarcoma/PNET, neuroblastoma, alveolar rhabdomyosarcoma, malignant mesothelioma must be excluded.
  • Cytogenetic examination should be performed on tumours with a "non-typical" histological pattern and uncommon immunohistological examinations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874904.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


23. Marcy PY, Magné N, Bentolila F, Drouillard J, Bruneton JN, Descamps B: Superior vena cava obstruction: is stenting necessary? Support Care Cancer; 2001 Mar;9(2):103-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No therapy is currently available for patients with recurrent vascular obstruction of the superior vena cava (SVC) caused by tumor regrowth after chemotherapy or radiation therapy.
  • Intravascular stenting is a new option for the treatment of vena cava syndrome.
  • Forty cancer patients with SVC syndrome (SVCS) were evaluated by computed tomography (CT) and venography.
  • The etiology was malignant in all but 2 cases: non-small-cell lung carcinoma (n = 28), mediastinal nodal metastasis (n = 5), lymphoma (n = 2), pleural mesothelioma (n = 2), small-cell lung carcinoma (n = 1), and postradiation fibrous mediastinitis (n = 2).
  • [MeSH-major] Stents. Superior Vena Cava Syndrome / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305067.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Hillerdal G, Elmberger G: Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma? J Thorac Oncol; 2007 Oct;2(10):983-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma?
  • Mesothelioma can occur in different variants, some of which are difficult or impossible to differentiate from sarcomas.
  • There are scattered reports of sarcomatous mesotheliomas that have osteogenic properties.
  • Here, we report a 57-year old man who presented with a mediastinal tumor containing scattered irregular calcifications with some scattered pleural thickening of the right pleura.
  • Biopsy showed a sarcoma with bone formation.
  • The man was born in the Turkish village of Karain, where the incidence of mesothelioma is extremely high, and a sarcomatous mesothelioma was therefore diagnosed.
  • Since the tumor was pressing against the large vessels and heart, a debulking was performed, followed by Pemetrexed and Carboplatin treatment.
  • This is to our knowledge the first report of a sarcomatous mesothelioma with bone formation from environmental exposure to mineral fibers.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mesothelioma / pathology. Osteogenesis. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcification, Physiologic. Carboplatin / administration & dosage. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Pemetrexed. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / etiology. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Thoracoscopy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909365.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


25. Heintz NH, Janssen-Heininger YM, Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol; 2010 Feb;42(2):133-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen years have passed since we published findings in the AJRCMB demonstrating that induction of early response fos/jun proto-oncogenes in rodent tracheal and mesothelial cells correlates with fibrous geometry and pathogenicity of asbestos.
  • Our study was the first to suggest that the aberrant induction of signaling responses by crocidolite asbestos and erionite, a fibrous zeolite mineral associated with the development of malignant mesotheliomas (MMs) in areas of Turkey, led to altered gene expression.
  • New data questioned the widely held belief at that time that the carcinogenic effects of asbestos in the development of lung cancer and MM were due to genotoxic or mutagenic effects.
  • An understanding of the pathogenic features of asbestos fibers and dysregulation of signaling pathways allows strategies for the prevention and therapy of asbestos-related diseases.
  • [MeSH-major] Asbestos / toxicity. Lung Neoplasms / etiology. Mesothelioma / etiology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Humans. MAP Kinase Signaling System / drug effects. Models, Biological. NF-kappa B / metabolism. Oxidants / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Proto-Oncogene Proteins c-jun / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Signal Transduction / drug effects. Transcription Factor AP-1 / metabolism

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 1994 Nov;11(5):522-30 [7946382.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2085-9 [7743507.001]
  • [Cites] Am J Respir Cell Mol Biol. 1995 Jun;12(6):676-83 [7539275.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2723-6 [7796393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8458-62 [7667311.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1987-2001 [7560092.001]
  • [Cites] Free Radic Biol Med. 1996;21(2):125-31 [8818626.001]
  • [Cites] Carcinogenesis. 1996 Nov;17(11):2525-7 [8968073.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):825-32 [9111221.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3101-5 [9242432.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):389-401 [9250152.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):265-71 [9308911.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3574-81 [18982164.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):449-59 [19116364.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Jul;41(1):114-23 [19097984.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Apr;24(4):405-13 [11306433.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1307-16 [10751356.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1115-9 [11007949.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L916-23 [11053028.001]
  • [Cites] Carcinogenesis. 2000 Dec;21(12):2275-80 [11133818.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1018-25 [12909582.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):805-13 [14737115.001]
  • [Cites] Int J Oncol. 2004 Jul;25(1):173-8 [15202003.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6530-6 [15374964.001]
  • [Cites] J Natl Cancer Inst. 1979 Jul;63(1):17-22 [286826.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):9405-14 [11756413.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6065-9 [12414630.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):713-20 [12598305.001]
  • [Cites] Free Radic Biol Med. 2003 May 1;34(9):1117-29 [12706492.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3539-45 [12839939.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Aug;29(2):198-205 [12626342.001]
  • [Cites] N Engl J Med. 1989 Jun 29;320(26):1721-30 [2659987.001]
  • [Cites] Science. 1990 Jan 19;247(4940):294-301 [2153315.001]
  • [Cites] Environ Health Perspect. 1997 Sep;105 Suppl 5:1073-84 [9400703.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):333-40 [9466557.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):367-72 [9708797.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 May;20(5):942-52 [10226064.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 1):L684-93 [10516208.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):835-42 [15897248.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4716-27 [15930290.001]
  • [Cites] Semin Respir Crit Care Med. 2005 Jun;26(3):314-22 [16052433.001]
  • [Cites] Mol Cancer Ther. 2005 Aug;4(8):1146-56 [16093430.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6080-9 [15897870.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):70-7 [16169567.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):21-44 [16393692.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Apr;34(4):443-52 [16357363.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):524-33 [16415123.001]
  • [Cites] FASEB J. 2006 May;20(7):997-9 [16571779.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jun;290(6):C1532-42 [16394028.001]
  • [Cites] J Histochem Cytochem. 2006 Aug;54(8):855-61 [16517979.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2406-13 [17557954.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2092-102 [17620438.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5942-51 [17908991.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Feb;38(2):209-17 [17872495.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):107-10 [18048409.001]
  • [Cites] Mol Cancer. 2007;6:81 [18096084.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2391-9 [18381447.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 May;38(5):618-26 [18192500.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Apr;21(2):117-22 [18384505.001]
  • [Cites] Science. 2008 May 2;320(5876):674-7 [18403674.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1365-74 [18049451.001]
  • [Cites] Immunol Rev. 2008 Jun;223:20-38 [18613828.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):808-14 [18543326.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3651-9 [18949058.001]
  • [Cites] Am Rev Respir Dis. 1990 May;141(5 Pt 1):1266-71 [2160214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7385-9 [2170975.001]
  • [Cites] Carcinogenesis. 1991 Aug;12(8):1499-502 [1650293.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10625-30 [1316905.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):475-85 [1323223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3299-303 [8386370.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):795-802 [8118652.001]
  • [CommentIn] Am J Respir Cell Mol Biol. 2010 Feb;42(2):131-2 [20068226.001]
  • (PMID = 20068227.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Oxidants; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Receptors, Tumor Necrosis Factor; 0 / Transcription Factor AP-1; 1332-21-4 / Asbestos; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 78
  • [Other-IDs] NLM/ PMC2822975
  •  go-up   go-down






Advertisement